Commentary

Published in:
Volume 7 / Year 2018 / Issue 2

Potential changes to the FDA approach to biosimilars have a global impact

Author(s):

Abstract: The article of Niazi urges the US Food and Drug Administration (FDA) to make adjustments to its guidance on biosimilar development. This article comments some of the proposals from… Read More »

Go Back Print